Research news

The Com-Cov trial in which UCLH is a site looking at alternating vaccines has been expanded to include the Moderna and Novavax vaccines.

Achilles Therapeutics, a company built on research at UCLH, UCL Cancer Institute and the Francis Crick Institute has successfully raised $175.5 million through its initial public offering in the United States.

A front page story and patient case study highlight SUMMIT Study early diagnosis outcomes.

In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.

The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.